Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
200%(4 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_3
3
75%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
3(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(2)

Detailed Status

Terminated2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (25.0%)
Phase 33 (75.0%)

Trials by Status

terminated250%
completed250%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_3

Open-Label Extension Study of Trofinetide for Rett Syndrome

NCT04776746
terminatedphase_2

An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome

NCT04988867
completedphase_3

Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

NCT04279314
completedphase_3

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

NCT04181723

Clinical Trials (4)

Showing 4 of 4 trials
NCT04776746Phase 3

Open-Label Extension Study of Trofinetide for Rett Syndrome

Terminated
NCT04988867Phase 2

An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome

Terminated
NCT04279314Phase 3

Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

Completed
NCT04181723Phase 3

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4